FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056220279> ?p ?o ?g. }

• W2056220279 endingPage "275" @default.
• W2056220279 startingPage "270" @default.
• W2056220279 abstract "Background Nimotuzumab (TheraCIM®) is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) with minimal skin toxicity. Combining a different class of anti-EGFR drug with gefitinib is a new strategy to overcome intrinsic and acquired resistance to gefitinib. The aim of this phase I trial was to determine recommended phase II dose (RPIID) and the safety of gefitinib and nimotuzumab combination treatment. Methods Patients with advanced/metastatic NSCLC were treated with escalating doses of weekly nimotuzumab (100 mg or 200 mg, IV) and fixed doses of daily gefitinib (250 mg/day, PO) until disease progression or unacceptable toxicity. We planned to enroll 10 additional patients at RPIID to ascertain the safety of treatment. EGFR mutations and KRAS mutations were analyzed from available tumor samples. Results A total of 16 patients were enrolled (3 in 100 mg cohort, 13 in 200 mg cohort). Six patients (37.5%) were female, and 5 (31.3%) were never smokers. Adenocarcinoma was the major histologic type (13 patients, 81.3%). Treatment was well-tolerated without dose-limiting toxicity (DLT). Four patients (25.0%) experienced grade 2 skin toxicity (1 in 100 mg cohorts, 3 in 200 mg cohort). Other common grade 1/2 toxicities were fatigue (37.5%) and diarrhea (25.0%). Among 16 evaluable patients, four patients (25.0%) achieved partial response and 7 patients (43.8%) had stable disease. Two of 4 responders had EGFR mutation (exon 19 deletion). Conclusions Dual agent molecular targeting of EGFR with nimotuzumab and gefitinib in patients with advanced NSCLC is well-tolerated. The RPIID for nimotuzumab is 200 mg weekly IV and for gefitinib 250 mg/day PO. Based upon this phase I trial, we are planning to conduct a randomized phase II trial comparing gefitinib and nimotuzumab with gefitinib alone in patients with advanced NSCLC." @default.
• W2056220279 created "2016-06-24" @default.
• W2056220279 creator A5004798515 @default.
• W2056220279 creator A5005358526 @default.
• W2056220279 creator A5010511810 @default.
• W2056220279 creator A5020903295 @default.
• W2056220279 creator A5030461914 @default.
• W2056220279 creator A5042963282 @default.
• W2056220279 creator A5047490140 @default.
• W2056220279 creator A5061104024 @default.
• W2056220279 creator A5063587278 @default.
• W2056220279 creator A5064697305 @default.
• W2056220279 creator A5066445933 @default.
• W2056220279 creator A5084556406 @default.
• W2056220279 creator A5087673406 @default.
• W2056220279 date "2013-03-01" @default.
• W2056220279 modified "2023-10-06" @default.
• W2056220279 title "A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)" @default.
• W2056220279 cites W1994225895 @default.
• W2056220279 cites W1998971866 @default.
• W2056220279 cites W2002937040 @default.
• W2056220279 cites W2003984225 @default.
• W2056220279 cites W2005312471 @default.
• W2056220279 cites W2019607817 @default.
• W2056220279 cites W2029633750 @default.
• W2056220279 cites W2037139573 @default.
• W2056220279 cites W2043696829 @default.
• W2056220279 cites W2048733384 @default.
• W2056220279 cites W2071803372 @default.
• W2056220279 cites W2073464554 @default.
• W2056220279 cites W2073541926 @default.
• W2056220279 cites W2083517004 @default.
• W2056220279 cites W2094417916 @default.
• W2056220279 cites W2099618978 @default.
• W2056220279 cites W2108572942 @default.
• W2056220279 cites W2112602910 @default.
• W2056220279 cites W2115131874 @default.
• W2056220279 cites W2121389354 @default.
• W2056220279 cites W2129432386 @default.
• W2056220279 cites W2131597845 @default.
• W2056220279 cites W2133741785 @default.
• W2056220279 cites W2135293060 @default.
• W2056220279 cites W2137600224 @default.
• W2056220279 cites W2139236349 @default.
• W2056220279 cites W2150308444 @default.
• W2056220279 cites W2155933329 @default.
• W2056220279 cites W2159013299 @default.
• W2056220279 cites W2161821474 @default.
• W2056220279 cites W2165755768 @default.
• W2056220279 cites W2166084034 @default.
• W2056220279 cites W2332183914 @default.
• W2056220279 cites W4234236664 @default.
• W2056220279 doi "https://doi.org/10.1016/j.lungcan.2012.11.017" @default.
• W2056220279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23261229" @default.
• W2056220279 hasPublicationYear "2013" @default.
• W2056220279 type Work @default.
• W2056220279 sameAs 2056220279 @default.
• W2056220279 citedByCount "18" @default.
• W2056220279 countsByYear W20562202792013 @default.
• W2056220279 countsByYear W20562202792014 @default.
• W2056220279 countsByYear W20562202792015 @default.
• W2056220279 countsByYear W20562202792016 @default.
• W2056220279 countsByYear W20562202792017 @default.
• W2056220279 countsByYear W20562202792018 @default.
• W2056220279 countsByYear W20562202792019 @default.
• W2056220279 countsByYear W20562202792021 @default.
• W2056220279 countsByYear W20562202792022 @default.
• W2056220279 crossrefType "journal-article" @default.
• W2056220279 hasAuthorship W2056220279A5004798515 @default.
• W2056220279 hasAuthorship W2056220279A5005358526 @default.
• W2056220279 hasAuthorship W2056220279A5010511810 @default.
• W2056220279 hasAuthorship W2056220279A5020903295 @default.
• W2056220279 hasAuthorship W2056220279A5030461914 @default.
• W2056220279 hasAuthorship W2056220279A5042963282 @default.
• W2056220279 hasAuthorship W2056220279A5047490140 @default.
• W2056220279 hasAuthorship W2056220279A5061104024 @default.
• W2056220279 hasAuthorship W2056220279A5063587278 @default.
• W2056220279 hasAuthorship W2056220279A5064697305 @default.
• W2056220279 hasAuthorship W2056220279A5066445933 @default.
• W2056220279 hasAuthorship W2056220279A5084556406 @default.
• W2056220279 hasAuthorship W2056220279A5087673406 @default.
• W2056220279 hasConcept C121608353 @default.
• W2056220279 hasConcept C126322002 @default.
• W2056220279 hasConcept C143998085 @default.
• W2056220279 hasConcept C2776055544 @default.
• W2056220279 hasConcept C2776256026 @default.
• W2056220279 hasConcept C2779177807 @default.
• W2056220279 hasConcept C2779438470 @default.
• W2056220279 hasConcept C2779984678 @default.
• W2056220279 hasConcept C2780580887 @default.
• W2056220279 hasConcept C2781187634 @default.
• W2056220279 hasConcept C29730261 @default.
• W2056220279 hasConcept C31760486 @default.
• W2056220279 hasConcept C526805850 @default.
• W2056220279 hasConcept C71924100 @default.
• W2056220279 hasConcept C72563966 @default.
• W2056220279 hasConcept C81729549 @default.
• W2056220279 hasConceptScore W2056220279C121608353 @default.

• next